Personalizing therapy for ovarian cancer: BRCAness and beyond

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3545-3548

  Bast Jr , Robert C ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; B RAF KINASE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH3 RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51 PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR; STAT3 PROTEIN; TAMOXIFEN; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; COMPETITIVE INHIBITION; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EDITORIAL; ENZYME ACTIVATION; EXCISION REPAIR; FAMILY HISTORY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; LIPOSOMAL DELIVERY; MOLECULAR DIAGNOSIS; MOLECULAR THERAPY; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECURRENT CANCER; REIMBURSEMENT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; FEMALE; GENETICS; METHODOLOGY; MUTATION; NOTE; OVARY TUMOR; PERSONALIZED MEDICINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; FEMALE; GENE EXPRESSION PROFILING; GENES, BRCA1; GENES, BRCA2; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77955911553     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.5791     Document Type: Editorial

References (28)

1. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009
2. Yap TA, Carden GP, Kaye SB: Beyond chemotherapy: Targeted chemotherapy for ovarian cancer. Nat Rev Cancer 9:167-181, 2009
3. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
4. Hennessy B, Timms K, Carey MS, et al: Somatic BRCA status in ovarian tumors. J Clin Oncol 27:284s, 2009 (suppl; abstr 5528)
5. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333, 2000
6. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94:61-67, 2002 (Pubitemid 34082844)
7. Esteller M, Silva JM, Dominquez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000 (Pubitemid 30212318)
8. Hughes-Davies L, Huntsman D, Ruas M, et al: EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523-535, 2003 (Pubitemid 37506042)
9. Konstantinopoulos PA, Spentzos D, Karlan BY, et al: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555-3561, 2010
10. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003 (Pubitemid 36444059)
11. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
12. Tan DS, Rothermundt C, Thomas K, et al: BRCAness syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536, 2008
13. Kurman RJ, Shih LE: Pathogenesis of ovarian cancer: Lessons from morphology and biology and their clinical implications. Int J Gynecol Pathol 27:151-160, 2008 (Pubitemid 351450677)
14. Bast RC, Hennessy B, Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9:415-428, 2009
15. Kohler MF, Kerns BJM, Soper JT, et al: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643-650, 1993 (Pubitemid 23137227)
16. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 18:106-115, 2000 (Pubitemid 30036343)
17. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996 (Pubitemid 26012496)
18. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results. J Natl Cancer Inst 92:699-708, 2000 (Pubitemid 30365530)
19. Stanislaus R, Carey M, Deus HF, et al: RPPAML/RIMS: A metadata format and an information management system for reverse phase protein arrays. BMC Bioinformatics 9:555, 2008
20. Zhang L, Wei Q, Mao L, et al: Serial dilution curve: A new method for analysis of reverse phase protein array data. Bioinformatics 25:650-654, 2009
21. Wong KK, Tsang YTM, Zu Z, et al: Insulin growth factor 1 pathway is a potential therapeutic target for low-grade ovarian cancers. Gynecol Oncol (in press)
22. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
23. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
24. Ahmed A, Le XF, Lu Z, et al. Kinase regulated microtubule stabilization correlates with paclitaxel response in a target specific siRNA kinome screen. Proc Am Assoc Cancer Res 50, 2009 (abstr 3869)
25. Ahmed A, Jacomo RO, Lu Z, et al: The salt inducible kinase 2 (SIK2) is required for centrosome separation at the onset of mitosis. Proc Am Assoc Cancer Res 50, 2009 (abstr LB-43)
26. Ahmed AA, Le X-F, Lu Z, et al: Loss of CDK5 sensitizes cells to paclitaxel by enhancing intracellular retention. Proc Am Assoc Cancer Res 57, 2010 (abstr 1585)
27. Whitehurst AW, Bodemann BO, Cardenas J, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819, 2007 (Pubitemid 46582032)
28. Landen CN Jr, Chavez-Reyes A, Bucana C, et al: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910-6918, 2005 (Pubitemid 41060730)